TheraRadar
← Back
Data updated: Jul 17, 2026

ROBINS AH

Big Pharma

ROBINS AH is a major pharmaceutical company focused on Cardiovascular, Gastroenterology.

1960
Since
10
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

ROBINS AH's Key Drugs

ROBINS AH's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ROBINS AH's Recent FDA Approvals

New NDA/BLA approvals for ROBINS AH over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ROBINS AH's Therapeutic Areas

ROBINS AH's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Gastroenterology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 50%
1 drugs
Gastroenterology 50%
1 drugs

ROBINS AH's Top Competitors

ROBINS AH's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Takeda, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ROBINS AH Pipeline Snapshot

Active clinical trials for ROBINS AH across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling